Korean J Radiol.  2014 Dec;15(6):817-826. 10.3348/kjr.2014.15.6.817.

Radiofrequency Ablation to Treat Loco-Regional Recurrence of Well-Differentiated Thyroid Carcinoma

• Lee SJ
• Jung SL
• Kim BS
• Ahn KJ
• Choi HS
• Lim DJ
• Kim MH
• Bae JS
• Kim MS
• Jung CK
• Chong SM

• KMID: 1794655
• DOI: http://doi.org/10.3348/kjr.2014.15.6.817

Abstract

OBJECTIVE
To evaluate the efficacy of radiofrequency ablation (RFA) in the treatment of loco-regional, recurrent, and well-differentiated thyroid carcinoma.
MATERIALS AND METHODS
Thirty-five recurrent well-differentiated thyroid carcinomas (RTC) in 32 patients were treated with RFA, between March 2008 and October 2011. RTCs were detected by regular follow-up ultrasound and confirmed by biopsy. All patients had fewer than 3 RTCs in the neck and were at high surgical risk or refused to undergo repeated surgery. Average number of RFA sessions were 1.3 (range 1-3). Post-RFA biopsy and ultrasound were performed. The mean follow-up period was 30 months. Pre- and post-RFA serum thyroglobulin values were evaluated.
RESULTS
Thirty-one patients with 33 RTCs were treated with RFA only, whereas 1 patient with 2 RTCs was treated with RFA followed by surgery. At the last follow-up ultrasound, 31 (94%) of the 33 RTCs treated with RFA alone completely disappeared and the remaining 2 (6%) RTCs showed decreased volume. The largest diameter and volume of the 33 RTCs were markedly decreased by 93.2% (from 8.1 +/- 3.4 mm to 0.6 +/- 1.8 mm, p < 0.001) and 96.4% (from 173.9 +/- 198.7 mm3 to 6.2 +/- 27.9 mm3, p < 0.001), respectively. Twenty of the 21 RTCs evaluated with post-RFA biopsies (95%) were negative for malignancy. One (5%) showed remaining tumor that was removed surgically. The serum thyroglobulin was decreased in 19 of 26 patients (73%). Voice change developed immediately after RFA in 6 patients (19%) and was spontaneously recovered in 5 patients (83%).
CONCLUSION
Radiofrequency ablation can be effective in treating loco-regional, recurrent, and well-differentiated thyroid carcinoma in patients at high surgical risk.

Keyword

Radiofrequency ablation; Recurrent thyroid cancer; Efficacy; Thyroid; Ultrasound

MeSH Terms

Adult
Aged
Aged, 80 and over
Carcinoma/*pathology/surgery/ultrasonography
Catheter Ablation
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Thyroglobulin/blood
Thyroid Neoplasms/*pathology/surgery/ultrasonography
Tomography, X-Ray Computed
Thyroglobulin

Figure

• 

  Fig. 1 Three procedures to prevent major organ injuries near tumors in level 6. Metastatic tumor is detected in right level 6 on ultrasound (A, straight arrows). First, lidocaine is injected around tumor to separate invisible recurrent laryngeal nerve, trachea, and carotid artery from tumor and to provide pain control before ablation (B, arrowheads). Second, tumor is pulled away from three organs by tilting electrode during ablation (C, D, curved arrows). Third, cold fluid is injected around ablated tumor after ablation (E, arrowheads).

• 

  Fig. 2 Three procedures to prevent major organ injuries near tumor in level 3. Metastatic tumor (arrowhead) in right level 3 is detected near vagus nerve (straight arrow), common carotid artery (CCA) and internal jugular vein (IJV) on ultrasound (A). First, lidocaine is injected around tumor to separate visible vagus nerve (short arrow), CCA, IJV, and sternocleidomastoid muscle from tumor and to provide pain control before ablation (B, C, arrowheads). Second, tumor is pulled away from three major organs by tilting electrode during ablation (D, curved arrow). Third, cold fluid is injected around ablated tumor after ablation (not shown).

• 

  Fig. 3 39-year-old man with recurrent thyroid cancer in right level 3. Initial CT (A) and ultrasound (B) demonstrate recurrent nodule in right level 3 (arrows, 13 mm). One session of radiofrequency ablation (RFA) (1.0-cm electrode, 10-20 W, one minutes 20 seconds) is performed. Nodule shows decreased size with 76.9% volume reduction rate on post-RFA one-month follow-up ultrasound (not shown) and is invisible on 19-month follow-up ultrasound (C, arrows) and 22-month follow-up CT (D, arrows).

• 

  Fig. 4 38-year-old woman with recurrent thyroid cancer in right level 6. Initial CT (A) and ultrasound (B) show enhancing nodule in right level 6 (arrows, 18 mm). There is no enhancing nodule (arrows) on 2-month follow-up CT after radiofrequency ablation (RFA) (C). On ultrasound for post-RFA fine-needle aspiration (D), volume of this nodule was markedly reduced (87.0% volume reduction rate) and biopsy result was negative for malignancy.

• 

  Fig. 5 85-year-old woman with two recurrent thyroid cancers in right level 4 (23 mm and 26 mm). Recurrent node (23 mm) is seen on initial CT (A, arrows). Volume of this node is reduced, but it is still enhanced on CT scan after 1st radiofrequency ablation (RFA) (B, arrows). Suspicion of malignancy was demonstrated in this nodule on post-1st RFA biopsy. This nodule was surgically treated (C, arrows). Another recurrent node (26 mm) was completely treated with RFA (not shown).

Reference

1. Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Philadelphia: Saunders;2014. p. 1073–1139.

2. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer. 1997; 79:564–573.

3. Dupuy DE, Monchik JM. Radiofrequency ablation of recurrent thyroid cancer. In : Ellis LM, Curley SA, Tanabe KK, editors. Radiofrequency Ablation for Cancer: Current indications, techniques, and outcomes. New York: Springer-Verlag;2003. p. 213–223.

4. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab. 1997; 82:3553–3562.

5. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab. 1992; 75:714–720.

6. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 1981; 70:511–518.

7. Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB. Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery. 2001; 130:921–930.

8. Dupuy DE, Monchik JM, Decrea C, Pisharodi L. Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery. 2001; 130:971–977.

9. Monchik JM, Donatini G, Iannuccilli J, Dupuy DE. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg. 2006; 244:296–304.

10. Baek JH, Kim YS, Sung JY, Choi H, Lee JH. Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ablation. AJR Am J Roentgenol. 2011; 197:W331–W336.

11. Shin JE, Baek JH, Lee JH. Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers: current status and challenges. Curr Opin Oncol. 2013; 25:14–19.

12. Park KW, Shin JH, Han BK, Ko EY, Chung JH. Inoperable symptomatic recurrent thyroid cancers: preliminary result of radiofrequency ablation. Ann Surg Oncol. 2011; 18:2564–2568.

13. Lewis BD, Hay ID, Charboneau JW, McIver B, Reading CC, Goellner JR. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol. 2002; 178:699–704.

14. Na DG, Lee JH, Jung SL, Kim JH, Sung JY, Shin JH, et al. Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations. Korean J Radiol. 2012; 13:117–125.

15. Baek JH, Lee JH, Sung JY, Bae JI, Kim KT, Sim J, et al. Complications encountered in the treatment of benign thyroid nodules with US-guided radiofrequency ablation: a multicenter study. Radiology. 2012; 262:335–342.

16. Goldberg SN, Charboneau JW, Dodd GD 3rd, Dupuy DE, Gervais DA, Gillams AR, et al. Image-guided tumor ablation: proposal for standardization of terms and reporting criteria. Radiology. 2003; 228:335–345.

17. Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol. 2003; 14(9 Pt 2):S199–S202.

18. Papini E, Bizzarri G, Bianchini A, Valle D, Misischi I, Guglielmi R, et al. Percutaneous ultrasound-guided laser ablation is effective for treating selected nodal metastases in papillary thyroid cancer. J Clin Endocrinol Metab. 2013; 98:E92–E97.

19. Mauri G, Cova L, Tondolo T, Ierace T, Baroli A, Di Mauro E, et al. Percutaneous laser ablation of metastatic lymph nodes in the neck from papillary thyroid carcinoma: preliminary results. J Clin Endocrinol Metab. 2013; 98:E1203–E1207.

20. Pacella CM, Bizzarri G, Guglielmi R, Anelli V, Bianchini A, Crescenzi A, et al. Thyroid tissue: US-guided percutaneous interstitial laser ablation-a feasibility study. Radiology. 2000; 217:673–677.